Literature DB >> 2138064

Ondansetron--a new safe and effective antiemetic in patients receiving high-dose melphalan.

C V Viner1, P J Selby, G B Zulian, M E Gore, M E Butcher, C M Wootton, T J McElwain.   

Abstract

A total of 33 patients with myeloma receiving treatment with high-dose melphalan (140-200 mg/m2 i.v.) were given the 5HT3 antagonist Ondansetron (Glaxo) as an antiemetic. In 42% of patients, emetic episodes were either abolished (15%) or reduced to two or less (27%). Efficacy was not related to scheduling (two regimens) or total dose. No sedative or other significant side effects were seen. Ondansetron is a highly effective non-sedative antiemetic that justifies further assessment in combination with other antiemetics in patients receiving cytotoxic drugs associated with the production of severe nausea and vomiting.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2138064     DOI： 10.1007/bf00686058

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  11 in total

1.  Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy.

Authors:  M G Kris; R J Gralla; R A Clark; L B Tyson
Journal:  J Clin Oncol       Date:  1988-04       Impact factor: 44.544

2.  High-dose melphalan and autologous bone marrow transplant as treatment for refractory Hodgkin's disease.

Authors:  P J Selby; E K Mbidde; J Maitland; T J McElwain
Journal:  J Clin Oncol       Date:  1986-04       Impact factor: 44.544

3.  Melphalan and total body irradiation (TBI) versus cyclophosphamide and TBI as conditioning for allogeneic matched sibling bone marrow transplants for acute myeloblastic leukaemia in first remission.

Authors:  G Helenglass; R L Powles; T J McElwain; A Lakhani; S Milan; M Gore; A Nandi; A Zuiable; T Perren; G Forgeson
Journal:  Bone Marrow Transplant       Date:  1988-01       Impact factor: 5.483

4.  Multiple myeloma treated with high dose intravenous melphalan.

Authors:  P J Selby; T J McElwain; A C Nandi; T J Perren; R L Powles; C R Tillyer; R J Osborne; M L Slevin; J S Malpas
Journal:  Br J Haematol       Date:  1987-05       Impact factor: 6.998

5.  Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist.

Authors:  D Cunningham; J Hawthorn; A Pople; J C Gazet; H T Ford; T Challoner; R C Coombes
Journal:  Lancet       Date:  1987-06-27       Impact factor: 79.321

6.  High dose melphalan and non-cryopreserved autologous bone marrow treatment of malignant melanoma and neuroblastoma.

Authors:  T J McElwain; D W Hedley; M Y Gordon; M Jarman; J L Millar; J Pritchard
Journal:  Exp Hematol       Date:  1979       Impact factor: 3.084

7.  High-dose intravenous melphalan for plasma-cell leukaemia and myeloma.

Authors:  T J McElwain; R L Powles
Journal:  Lancet       Date:  1983-10-08       Impact factor: 79.321

8.  Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin.

Authors:  M G Kris; R J Gralla; R A Clark; L B Tyson
Journal:  J Natl Cancer Inst       Date:  1989-01-04       Impact factor: 13.506

9.  The efficacy of GR38032F, an antagonist of 5-hydroxytryptamine-3 (5-HT3) in the prophylaxis of cisplatin (CDDP)-induced nausea and vomiting.

Authors:  L D de Haan; P H de Mulder; L V Beex; F M Debruyne; T Challoner; B E de Pauw
Journal:  Eur J Cancer Clin Oncol       Date:  1988-08

10.  Pharmacokinetics and anti-emetic efficacy of BRL43694, a new selective 5HT-3 antagonist.

Authors:  J Cassidy; V Raina; C Lewis; L Adams; M Soukop; W G Rapeport; B D Zussman; E M Rankin; S B Kaye
Journal:  Br J Cancer       Date:  1988-11       Impact factor: 7.640
View more
  8 in total

Review 1.  Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement.

Authors:  Lawrence H Einhorn; Bernardo Rapoport; Jim Koeller; Steven M Grunberg; Petra Feyer; Cynthia Rittenberg; Matti Aapro
Journal:  Support Care Cancer       Date:  2004-10-09       Impact factor: 3.603

Review 2.  Pharmacological Agents Affecting Emesis : A Review (Part II).

Authors:  F Mitchelson
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

3.  The role of nitric oxide in serotonin-induced relaxations in the canine terminal ileum and ileocolonic junction.

Authors:  J J Bogers; P A Pelckmans; G E Boeckxstaens; J G De Man; A G Herman; Y M Van Maercke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-12       Impact factor: 3.000

4.  Efficacy of aprepitant in preventing nausea and vomiting due to high-dose melphalan-based conditioning for allogeneic hematopoietic stem cell transplantation.

Authors:  Masatoshi Sakurai; Takehiko Mori; Jun Kato; Yuya Koda; Taku Kikuchi; Sumiko Kohashi; Masuho Saburi; Takaaki Toyama; Yoshinobu Aisa; Tomonori Nakazato; Noriko Beppu; Soichiro Tsuda; Naoyuki Shigematsu; Shinichiro Okamoto
Journal:  Int J Hematol       Date:  2014-03-12       Impact factor: 2.490

Review 5.  Oncology.

Authors:  J S Malpas
Journal:  Postgrad Med J       Date:  1993-02       Impact factor: 2.401

Review 6.  Ondansetron. Therapeutic use as an antiemetic.

Authors:  R J Milne; R C Heel
Journal:  Drugs       Date:  1991-04       Impact factor: 9.546

7.  Open probability of homomeric murine 5-HT3A serotonin receptors depends on subunit occupancy.

Authors:  D D Mott; K Erreger; T G Banke; S F Traynelis
Journal:  J Physiol       Date:  2001-09-01       Impact factor: 5.182

8.  An open, randomized study to compare the efficacy and tolerability of tropisetron with that of a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis.

Authors:  B Sorbe; C Hallén; B Frankendal
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.